close

Fundraisings and IPOs

1 2 3 72
Number of results: 1430
Date Company Amount Funding type Investors Therapeutic area Type of Information
2018-10-10 Secarna Pharmaceuticals (Germany) grant European Commission’s Horizon 2020 programme Rare diseases - Fibrotic diseases - Lung diseases Grant
2018-10-10 Allogene Therapeutics (USA - CA) $324.0 million IPO Cancer - Oncology IPO
2018-10-10 Allogene Therapeutics (USA - CA) $324 million IPO Cancer - Oncology IPO
2018-10-10 Histogenics (USA - MA) $15.4 million private placement Regenerative Medicine - Bone diseases Private placement
2018-10-10 RoslinCT (UK) Reprocell (UK) £1.2 million grant Innovate UK (UK) Technology - Services Grant
2018-10-05 Epizyme (USA - MA)  $86.25 million private placement Cancer - Oncology - Rare diseases Private placement
2018-10-05 Alligator Bioscience (Sweden) 500 000 SEK (€ 47 845) grant Vinnova, Swedish Governmental Agency for Innovation Systems (Sweden) Cancer - Oncology Grant
2018-09-26 Minoryx Therapeutics (Spain) €21.3 million series B financing round Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain) Fund+ (Belgium) Idinvest Partners (France) Kurma Partners (France) Sambrinvest (Belgium) Kurma Partners (France) Ysios Capital (Spain) SFPI-FPIM, S.R.I.W Rare diseases Series B financing round
2018-09-20 Fate Therapeutics (USA - CA) private placement Cancer - Oncology - Immunological diseases Private placement
2018-09-20 Y-mAbs Therapeutics (USA - NY) IPO Cancer - Oncology IPO
2018-09-12 CODA Biotherapeutics (USA - CA) $19 million series A financing round MPM Capital (USA - MA) Versant Ventures (USA - CA) Astellas Venture Management (USA - CA) Novartis (Switzerland) Neurological diseases - CNS diseases Series A financing round
2018-09-12 Exocobio (Republic of Korea) $27 million series B financing round Seven Tree Equity Partners (Republic of Korea) CSQUARED Global Asset Management (Republic of Korea) TS Investment Partners (Dubai) K2 Investment, Intervest (Republic of Korea) KDB Capital (Republic of Korea) Atinum Investment (Republic of Korea) GU Equity Partners (Republic of Korea) QUANTUM Ventures Korea (Republic of Korea) Platinum technology Investment (Republic of Korea) Autoimmune diseases - Dermatological diseases Series B financing round
2018-09-07 Oasmia Pharmaceutical (Sweden) SEK 35.2 million private placement Cancer - Oncology Private placement
2018-09-06 Twentyeight-Seven Therapeutics (USA - MA) $65 million series A financing round MPM Capital (USA - MA) Novartis Venture Fund (USA - MA) Johnson & Johnson Innovation – JJDC (USA - NJ) Vertex Ventures (USA - CA) Longwood Fund (USA - MA) Astellas Venture Management (USA - CA) Cancer - Oncology Series A financing round
2018-09-06 Allogene Therapeutics (USA - CA) $120 Million financing round Cancer - Oncology Financing round
2018-09-05 Retrophin (USA - CA) $240 million private placement Rare diseases Private placement
2018-08-31 Antabio (France) € 12.5 million series A financing round iXO Private Equity (France) IRDI SORIDEC Gestion (France) Galia Gestion (France) Omnes Capital (France) BNP Paribas Développement (France) Sham Innovation Santé (Turenne Capital) (France) and company’s historical investors including former President of OM Pharma Christophe Ricard. Rare diseases - Infectious diseases Series A financing round
2018-08-13 Orchard Therapeutics (UK) $150 Million series C financing round ArrowMark Partners (USA - CO) Cormorant Asset Management (USA - MA) Foresite Capital (USA - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) Venrock (USA - CA) Foresite Capital (USA - NY) Sphera Global Healthcare (Spain) Medison Ventures Driehaus Capital Management (USA - IL) Ghost Tree Capital Group (USA - NY) Temasek (Singpore) Baillie Gifford (UK) Cowen Healthcare (USA - NY) Agent Capital (USA - MA) Rare diseases - Genetic diseases Series C financing round
2018-08-08 Beigene (China) $903 million IPO Cancer - Oncology IPO
2018-08-06 Pharmaxis (Australia) A$24 million (£13.4 million - €15.35 million) financing round Arix Bioscience (UK) BVF Partners (USA - CA) other existing shareholders Fibrotic diseases - Inflammatory diseases Financing round